Vertex Pharma cystic fibrosis med Kaftrio OK’d in Europe August 21, 2020

As expected, the European Commission approves Vertex Pharmaceuticals’ (NASDAQ:VRTX) Kaftrio (ivacaftor/tezacaftor/elexacaftor), a combination regimen with ivacaftor, for the treatment of cystic fibrosis patients at least 12 years old with one F508del mutation and one minimal function mutation or two F508del mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

In late June, the advisory group CHMP adopted a positive opinion backing approval.

https://seekingalpha.com/news/3607872-vertex-pharma-cystic-fibrosis-med-kaftrio-okd-in-europe